179337-70-3Relevant academic research and scientific papers
COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS
-
Page/Page column 164, (2010/02/11)
A combination therapy comprising administration of a carbamoylating chemotherapeutic agent in conjunction with administration of a selective iNOS inhibitor compound is disclosed. Optionally, resection and radiation therapy are provided with the therapeutic combination. A medicament comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound together with a pharmaceutically acceptable carrier is further disclosed. A kit comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound is further disclosed.
Synthesis and biological characterization of L-N6-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor
Hallinan, E. Ann,Tsymbalov, Sofya,Dorn, Clifford R.,Pitzele, Barnett S.,Hansen Jr., Donald W.,Moore, William M.,Jerome, Gina M.,Connor, Jane R.,Branson, Linda F.,Widomski, Deborah L.,Zhang, Yan,Currie, Mark G.,Manning, Pamela T.
, p. 1686 - 1689 (2007/10/03)
The 5-tetrazole amide of L-N6-(1-iminoethyl)lysine (L-NIL), L-N6-(1-iminoethyl)lysine 5-tetrazole amide (1), has been prepared and evaluated. In contrast to L-NIL, 1 is a stable, nonhygroscopic, crystalline solid. Unlike L-NIL, 1 has
